Novavax (NVV1) Income Statement
Novavax Income Statement
Last quarter (Q2 2026), Novavax's total revenue was $56.70M, a decrease of 76.30% from the same quarter last year. In Q2, Novavax's net income was $-53.39M. See Novavax’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 1.12B | $ 682.16M | $ 556.38M | $ 1.60B | $ 197.58M | |
| $ 1.05B | $ 479.42M | $ 212.61M | $ 696.31M | $ 197.58M | |
| $ 489.07M | $ 728.35M | $ 779.13M | $ 1.34B | $ 1.88B | |
| Depreciation and Amortization | $ 27.61M | $ 48.50M | $ 41.23M | $ 29.05M | $ 12.66M |
| $ 492.33M | $ -108.04M | $ -487.39M | $ -604.71M | $ -1.68B | |
| $ 563.27M | $ -248.93M | $ -566.51M | $ -644.74M | $ -1.69B | |
| $ -121.10M | $ 72.32M | $ 23.48M | $ -8.91M | $ -27.96M | |
| $ 442.17M | $ -176.62M | $ -543.03M | $ -653.65M | $ -1.71B | |
| $ 440.30M | $ -187.50M | $ -545.06M | $ -657.94M | $ -1.74B | |
| Per Share Metrics | |||||
| Basic EPS | $ 2.72 | $ -1.23 | $ -5.41 | $ -8.42 | $ -23.44 |
| Diluted EPS | $ 2.54 | $ -1.23 | $ -5.41 | $ -8.42 | $ -23.44 |
| Weighted Average Shares Outstanding | 161.99M | 152.19M | 100.77M | 78.18M | 74.40M |
| Weighted Average Shares Outstanding (Diluted) | 173.10M | 152.19M | 100.77M | 78.18M | 74.40M |
Currency in USD